Shares in AstraZeneca rose past their September 2024 peak today, hitting a fresh record high and cementing the company's position as the largest UK-listed stock by market value.
Today's surge added to the rally after forecast-beating quarterly earnings last week and a US drug-pricing deal in October that helped remove some policy uncertainty.
The US accounts for more than 40% of AstraZeneca's total sales.
AstraZeneca was up 2.5% after surging to as high as £134.6, giving it a market value of close to £210 billion.
The blue-chip FTSE index, meanwhile, rose 1.1% to new record highs of its own, after UK labour market data boosted expectations for a Bank of England rate cut next month.
